Clinical Trials Directory

If people join this study, they will be placed into one of two groups by chance. One group will have the usual surgery to remove the melanoma along with a procedure to check nearby lymph nodes. The other group will have only the surgery to remove the melanoma. After surgery, doctors will watch for any signs that the melanoma has come back. Participants will complete surveys about their health and quality of life every four months for the first two years. After that, they will continue seeing their doctors every six months for three more years. If the melanoma returns after the first two years, participants will be asked to complete another survey at that time.

We are doing this study to compare the usual treatments of surgery alone to using chemotherapy before surgery. We want to know if adding doxorubicin and ifosfamide chemotherapy for liposarcoma (LPS) or doxorubicin and dacarbazine chemotherapy for leiomyosarcoma (LMS) before surgery can improve the long-term survival for patients with these cancers.

We are doing this study to identify patients who have gene changes or mutations in their tumor(s) and might be eligible for treatment using a combination of targeted therapy options. This study is called ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice).

Taking part in this study involves one visit that lasts about thirty minutes. During the visit, participants will answer a short survey about their health and hearing. They will also give a small saliva sample and have a gentle swab placed in the nose. These steps do not hurt. The visit can be done in person at a clinic or another location, or sometimes from home if the person lives nearby. There is no cost to take part, and there is no payment for joining the study.

We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.